The intraperitoneal administration of GNF-2 significantly decreased the diabetes-induced increase in the expression of pro-inflammatory cytokines such as TNF-α and IL-1β mRNAs in the spinal cord tissues (Figure 8B). The gene discussed is TNF; the disease is diabetes mellitus.